ENTITY
RemeGen

RemeGen (9995 HK)

312
Analysis
Health Care • China
RemeGen is a China-based biopharmaceutical company dedicated to the discovery, development, production, and commercialization of innovative biological drugs. The company focuses on therapeutic antibody drugs, including antibody-drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies, and bispecific antibodies, for major diseases such as autoimmune disorders, oncology, and ophthalmology. Key products include Telitacicept (RC18) and Disitamab Vedotin (RC48). RemeGen was co-founded in 2008 and is headquartered in Yantai, Shandong Province, China.
more
•09 Feb 2024 18:50

[Blue Lotus Daily]: LKNCY/ZLAB/9995 HK/BGNE/9926 HK/1801 HK/1877 HK/ATAT/TCOM/1211 HK/LI/NIO/XPEV

​Local government plans to provide RMB600mn in travel subsidies; new regulations protect pricing of innovative drugs; Porsche's Taycan now has...

Share
•19 Jan 2024 14:14

[Blue Lotus Daily]: 1211HK/XPEV/NIO/9995HK/TCOM/1024HK/780HK/3690HK

​Xpeng and NIO's weekly sales weaken; RemeGen's ADC to Pfizer rumors may be returned; Ctrip partners with Kuaishou to boost travel products.

Share
•26 Dec 2023 17:07

[Blue Lotus Daily]: ATAT/600754 CH/1211 HK/LI/XPEV/NIO/ZLAB/ARGX/9995 HK/3692 HK

Jinjiang's Oct-Nov RevPAR recovered to 105% of 2019, outperforming industry average. Huawei Harmony Alliance to establish independent stores....

Share
•19 Dec 2023 13:46

[Blue Lotus Daily]: TCOM/HTHT/ATAT/MNSO/9995 HK/XPEV

​China's tourism OTA platform sees low user activity and weak year-end travel demand. Korea's Daiso acquires Japanese shareholder. Harbour BioMed...

Share
•15 Dec 2023 14:48

[Blue Lotus Daily]:LKNCY/1211 HK/300750 CH/TSLA/9995 HK

​Chinese BsAb ADC developer secures a license deal with Bristol-Myers Squibb. Luckin increases subsidies for franchisees during the winter. LGES...

Share
x